Background and Purpose-Exosomes play a pivotal role in neurogenesis. In the peri-infarct area after stroke, axons begin to regenerate but are inhibited by astrocyte scar formation. The direct effect and underlying molecular mechanisms of astrocyte-derived exosomes on axonal outgrowth after ischemia are not known. Methods-Using a semaphorin 3A (Sema3A) inhibitor, we explored neuronal signaling during axonal outgrowth after ischemia in rats subjected to middle cerebral artery occlusion and in cultured cortical neurons challenged with oxygenglucose deprivation. Furthermore, we assessed whether this inhibitor suppressed astrocyte activation and regulated astrocyte-derived exosomes to enhance axonal outgrowth after ischemia. Results-In rats subjected to middle cerebral artery occlusion, we administered a Sema3A inhibitor into the peri-infarct area from 7 to 21 days after occlusion. We found that phosphorylated high-molecular weight neurofilament-immunoreactive axons were increased, glial fibrillary acidic protein-immunoreactive astrocytes were decreased, and functional recovery was promoted at 28 days after middle cerebral artery occlusion. In cultured neurons, the Sema3A inhibitor decreased Rho family GTPase 1, increased R-Ras, which phosphorylates Akt and glycogen synthase kinase 3β (GSK-3β), selectively increased phosphorylated GSK-3β in axons, and thereby enhanced phosphorylated high-molecular weight neurofilamentimmunoreactive axons after oxygen-glucose deprivation. In cultured astrocytes, the Sema3A inhibitor suppressed activation of astrocytes induced by oxygen-glucose deprivation. Exosomes secreted from ischemic astrocytes treated with the Sema3A inhibitor further promoted axonal elongation and increased prostaglandin D 2 synthase expression on microarray analysis. GSK-3β + and prostaglandin D 2 synthase + neurons were robustly increased after treatment with the Sema3A inhibitor in the peri-infarct area. Conclusions-Neuronal Rho family GTPase 1/R-Ras/Akt/GSK-3β signaling, axonal GSK-3β expression, and astrocyte-derived exosomes with prostaglandin D 2 synthase expression contribute to axonal outgrowth and functional recovery after stroke. Visual Overview-An online visual overview is available for this article.
A cute stroke therapies, such as recombinant human tissuetype plasminogen activator administration and endovascular thrombectomy, effectively reduce mortality and alleviate neurological deficits. 1, 2 However, ≈40% of stroke survivors display poor functional outcomes after such treatments. 2 Therapies to enhance axonal outgrowth and improve functional recovery are urgently needed.
In the chronic stage after stroke, axonal regeneration is related to functional recovery and is induced especially in the peri-infarct area. However, intrinsic signals such as the cAMP signaling pathway and inhibitory extrinsic factors limit axonal regeneration. [3] [4] [5] In particular, glial activation and scar formation, which create major inhibitory environments for axonal outgrowth in the peri-infarct area, also occur after stroke. 6, 7 Extracellular vesicles, such as exosomes, which are 40 to 100 nm in diameter, contain microRNAs, mRNAs, and proteins and are released via the endocytic pathway. Important recent research provides new insight showing that exosomes play important roles in intercellular communication, such as neuron-glial interactions. Exosomes are also implicated in the mechanism of neurogenesis after stroke.
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The semaphorins, which are secreted or membranebound proteins, are a large family of signaling molecules and axon guidance molecules. 10, 11 Semaphorin 3A (Sema3A) is an extracellular matrix molecule that inhibits axonal outgrowth. 11, 12 To date, the association of Sema3A with axonal regeneration and functional recovery after stroke has not been fully studied.
Taking advantage of these molecular mechanisms on axonal outgrowth, we report here novel mechanisms of axonal outgrowth and functional recovery after ischemia in association with inhibition of Sema3A in experimental rat brains. Our data suggest that regulation of not only neuronal signaling but also activated astrocytes and astrocyte-derived exosomes is a potential strategy for development of a novel therapeutic agent to improve functional outcome in the chronic stage of human stroke survivors.
Materials and Methods
All data and supporting materials are available with the article and its online-only Data Supplement. All experimental procedures were approved by the Animal Care Committee of Juntendo University (number: 290203).
Focal Cerebral Ischemia
Adult male Wistar/ST rats (8-10 weeks old, ≈320 g, Charles River, Kanagawa, Japan) were used in this study. Rats were subjected to permanent right middle cerebral artery occlusion (MCAO).
Behavioral Analyses
Motor functions were analyzed with the modified neurological severity score and rotarod test. 13, 14 Selective Inhibitor of Sema3A, an Inhibitor of Prostaglandin D 2 Synthase (PTGDS), and Experimental Groups In Vivo
We used SM-345431 (vinaxanthone), a small molecule Sema3A inhibitor (Sema3A-I), which was isolated from the culture broth of funbus Penicillium sp. strain SPF-3059. The detailed procedures for the fermentation and purification were described previously. 15 AT-56 (1 mg/kg; an inhibitor of PTGDS, Cayman Chemical, Ann Arbor, MI) was also administered into the peri-infarct area.
Primary Cortical Neurons
Cortical cells were harvested from embryonic day 17 Wistar rats (Charles River), according to a published protocol with minor modifications. 3 Oxygen-glucose deprivation (OGD) was performed for 3 hours.
Primary Astrocyte Cultures
Astrocytes were harvested from 0-to 2-day-old neonatal SpragueDawley rats according to a published protocol with minor modifications. 16 
Cell Viability Assays
Cell viability assays were performed.
Time-Lapse Microscopic Analysis
Time-lapse images to track axonal elongation in primary neuronal cultures grown in microfluidic chambers were obtained using a BioStation CT (Nikon, Tokyo, Japan) incubator equipped with a camera for video imaging.
Isolation of Astrocyte-Derived Exosomes
Exosomes were isolated by using ExoQuick-TC Exosome Precipitation Solution (System Bioscience, Mountain View, CA.
Application of Astrocyte-Derived Exosomes to Primary Neuronal Cultures
To examine the role of astrocyte-derived exosomes on axonal growth after ischemia, we applied astrocyte-derived exosomes to cultured cortical neurons challenged with OGD. We used microfluidic chambers to examine axonal elongation and placed 3×10 9 /mL astrocyte-derived exosomes into the somal compartment, 3×10 8 /mL astrocyte-derived exosomes into the axonal compartment, or these amounts into both compartments, according to a previous study.
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Immunohistochemistry and Immunocytochemistry
Immunofluorescent staining was performed (Table II in 
Western Blot
Protein extraction and electrophoresis of samples from cultured cortical neurons, astrocytes, and exosomes were performed.
Microarray Data Analysis
To analyze mRNAs and microRNAs, cultured cortical neurons and astrocyte-derived exosomes were lysed in Qiazol reagent, and total RNA was isolated using the miRNeasy Mini kit (Qiagen, Valencia, CA; n=4/group).
Image Acquisition and Quantification
Image Acquisition and Quantification was performed.
Statistical Analysis
Values presented in this study are expressed as the mean±SD. We calculated the sample size needed to detect a significant difference in the degree of motor recovery between the Sema3A-I treatment group and the control group according to a previous study (power, 80%; α=0.05) 18 ; a sample size of 6 rats per group was sufficient to detect differences in motor function. One-way ANOVA with post hoc Bonferroni correction was used. Survival curves were constructed using Kaplan-Meier survival analysis. Differences in survival curves were analyzed using the log-rank test. In microarray analysis, statistical significance was tested with an unpaired t test with GeneSpring software. A P<0.05 indicated a statistically significant difference. Analyses were performed using JMP (version 11.2, SAS Institute Inc, Cary, NC). Bar and line graphs were constructed with GraphPad Prism (version 5.0; GraphPad Software, Inc, La Jolla, CA).
Results
Temporal Profile of Sema3A Expression in the Peri-Infarct Area of Rat Brains
First, we analyzed the expression and temporal profile of Sema3A in the cerebral cortex using immunohistochemistry. Sema3A was colocalized with MAP2 (microtubule-associated protein 2) + cells but not phosphorylated high-molecular weight neurofilament (pNFH) + fibers (a marker of axons) in layer V of the cerebral cortex in the peri-infarct area ( Figure  IA in the online-only Data Supplement). The density of Sema3A + cells was increased from 3 to 14 days after MCAO and decreased by 56 days, whereas MAP2 + cells were substantially decreased at 3 days and then gradually increased by 56 days after MCAO ( Figure IB and IC in the online-only Data Supplement). Sema3A + -MAP2 + cells were significantly increased from 7 to 14 days and were then decreased at 56 days after MCAO. pNFH + axons were decreased at 7 days and then increased at 28 and 56 days after MCAO ( Figure IB and IC in the online-only Data Supplement).
Sema3A-I Improved Neurological Deficits and Motor Dysfunction After MCAO
To examine the effect of Sema3A inhibition on axonal outgrowth and motor function in MCAO rats, we administered the Sema3A-I or PBS in the peri-infarct area of MCAO rat brains ( Figure IIA in the online-only Data Supplement). Considering the temporal expression patterns of Sema3A after MCAO ( Figure IB and IC in the online-only Data Supplement), we administered the Sema3A-I from 7 to 21 days after MCAO. We found no significant differences in the survival rates ( Figure IIB in the online-only Data Supplement) or in the infarct area ( Figure III in the online-only Data Supplement) between MCAO rats treated with PBS and the Sema3A-I at any concentrations. Modified neurological severity score showed that rats treated with 3 mg/mL Sema3A-I displayed significant improvement from 14 to 28 days, whereas rats treated with 1 mg/mL Sema3A-I showed improved at 14 days compared with vehicle-treated rats ( Figure 1A ). Rats treated with 3 mg/mL Sema3A-I showed significant improvement in the rotarod test at 28 days compared with the vehicle-treated rats ( Figure 1B ).
Axonal Outgrowth and Activated Astrocytes in the Peri-Infarct Area
Double immunostaining revealed that the densities of Sema3A + and Sema3A + -MAP2 + neurons were decreased in a dose-dependent manner in rats treated with 0.1 (26.7% and 24.8%), 1 (16.6% and 20.4%), and 3 mg/mL (12.1% and 13.7%) Sema3A-I compared with vehicle-treated rats, respectively ( Figure 1C ). pNFH + axons were substantially increased in rats treated with the Sema3A-I compared with vehicle-treated rats (0.1 mg/mL, 184.1%; 1 mg/mL, 208.8%; 3 mg/mL, 296.8%), whereas GFAP (glial fibrillary acidic protein) + astrocytes were decreased by Sema3A-I treatment ( Figure 1D ). These data indicate that inhibition of Sema3A in the peri-infarct area in the subacute phase promoted axonal regeneration, suppressed activated astrocytes, and thereby enhanced functional recovery from stroke.
Sema3A Regulated pNFH Expression via Neuronal Signaling After Ischemia In Vitro
To examine the effect of Sema3A on axonal growth after ischemia, we analyzed the protein levels of pNFH in cultured cortical neurons treated with the Sema3A-I after OGD. We found no significant differences in cell viability after treatment with the Sema3A-I at different concentrations in cultured cortical neurons challenged with OGD ( Figure IV in the onlineonly Data Supplement). Western blot analysis with samples from cells 96 hours after OGD showed that the Sema3A-I increased pNFH (Figure 2A and 2B).
We next analyzed the signaling pathways that Sema3A regulates in relation to axonal outgrowth after ischemia.
Expression of Sema3A and Rho family GTPase 1 (Rnd1) was decreased by Sema3A-I treatment, whereas R-Ras levels were significantly increased after the Sema3A-I in a dose-dependent manner. Phosphorylated Akt and glycogen synthase kinase 3β (GSK-3β) levels were increased by Sema3A-I treatment. Protein levels of phosphorylated CRMP-2 (collapsin response mediator protein-2) at Thr-514 and Ser-522 were not different after Sema3A-I treatment (Figure 2A and 2B). Opposite effects by recombinant Sema3A conditioning were found in cultured cortical neurons challenged with OGD ( Figure V in the online-only Data Supplement). These data indicate that Sema3A regulates the Rnd1/R-Ras/Akt/GSK-3β signaling pathway, which is related to pNFH in cultured neurons after OGD.
Axonal Elongation and pGSK-3β in Regenerated Axons After Ischemia
To examine whether Sema3A regulated enhancement of axonal elongation after ischemia, we cultured cortical neurons in a microfluidic chamber. After OGD, 1 nmol/L recombinant Sema3A and 1 μmol/L Sema3A-I were applied to both axonal and somal compartments. Time-lapse data showed that axonal elongation per 30 minutes and the total elongation length >300 minutes in OGD neurons, OGD neurons conditioned with recombinant Sema3A, and OGD neurons treated with the Sema3A-I were 4.58±0.23 μm versus 2.44±0.27 μm versus 6.39±0.52 μm, and 45.84±4.66 μm versus 24.39±3.61 μm versus 63.85±6.21 μm, respectively ( Figure 3A and 3B) . At 270 minutes, OGD neurons treated with the Sema3A-I displayed longer axonal lengths than OGD neurons. At 90, and 210 to 300 minutes, the length of axons from baseline was significantly longer in OGD neurons treated with the Sema3A-I compared with recombinant Sema3A-treated OGD neurons ( Figure 3B ).
Next, we performed double immunofluorescent staining of pGSK-3β and pNFH in cultured primary cortical neurons grown in the microfluidic chamber. Compared with the density of pNFH + and GSK-3β + axons in the axonal compartment of OGD neurons, the Sema3A-I significantly increased the density of pNFH + axons (216.4%) and pGSK-3β + axons (188.8%), whereas recombinant Sema3A did not change the density of pNFH (125.3%) or pGSK-3β (94.6%; Figure 3C and 3D). Interestingly, the density of pNFH + -pGSK-3β + axons was substantially increased by 243.9% after Sema3A-I treatment ( Figure 3C and 3D) . Thus, our data indicate that the Sema3A-I increases the axonal distribution of pGSK-3β in regenerated axons.
Action of the Sema3A-I on Activated Astrocytes After Ischemia In Vitro
We next cultured primary astrocytes challenged with OGD to determine whether the inhibitor of Sema3A suppressed astrocytic activation after ischemia. In cultured astrocytes after OGD, cell viability did not change in different concentrations of the Sema3A-I (Figure VI in the online-only Data Supplement). The density of GFAP was increased in OGD astrocytes compared with non-OGD astrocytes, whereas OGD astrocytes treated with the Sema3A-I showed decreased GFAP
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October 2018 compared with OGD astrocytes (Figure 4A and 4B ). S100β (a marker of protoplasmic astrocytes) was decreased after OGD, and the Sema3A-I did not affect S100β ( Figure 4A and 4C). Western blot analysis showed that the Sema3A-I substantially decreased GFAP but not S100β (Figure 4C and  4D) . Expression of Sema3A was decreased in OGD astrocytes treated with 1 µmol/L Sema3A-I compared with OGD astrocytes ( Figure 4C and 4D) .
Exosomes in Cultured Astrocytes After Ischemia
Triple immunofluorescence showed that many exosomes containing CD63 and TSG101, markers of astrocyte-derived 
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October 2018 exosomes, 19 were present in the cell body and foot processes of GFAP + and S100β + astrocytes, indicating that exosomes were abundantly localized in reactive and protoplasmic astrocytes ( Figure 5A ). The density of CD63 and TSG101 exosomes in GFAP + and S100β + astrocytes, respectively, and protein levels of CD63 and TSG101 were not different among non-OGD astrocytes, OGD astrocytes, and OGD astrocytes treated with the Sema3A-I ( Figure VII in the online-only Data Supplement).
Astrocyte-Derived Exosomes for Axonal Elongation and Gene Expression
We next isolated exosomes from the medium of cultured astrocytes to analyze exosomes secreted from astrocytes. Electron microscopy showed that exosomes were present in medium harvested from OGD astrocytes and OGD astrocytes treated with the Sema3A-I ( Figure VIIIA and VIIIB in the online-only Data Supplement). The numbers of shedding microvesicles and exosomes were not significantly different among medium harvested from non-OGD astrocytes, OGD astrocytes, and OGD astrocytes treated with 0.1 and 1 μmol/L Sema3A-I ( Figure VIIIC and VIIID in the online-only Data Supplement). Table III in the online-only Data Supplement shows the distributions of exosomes by size among 4 different treatment groups, indicating that exosomes derived from OGD astrocytes had a higher concentration of smaller sized (<45.5 nm in diameter) exosomes. On microarray analysis, rno-miR30c-2-3p and rno-miR-326-5p were significantly downregulated in exosomes derived from OGD astrocytes treated with 1 μmol/L Sema3A-I relative to exosomes derived from OGD astrocytes (Table IV in the online-only Data Supplement).
We applied astrocyte-derived exosomes to cultured cortical neurons grown in microfluidic chambers after OGD, and timelapse data showed that the rates of axonal elongation per 30 minutes after OGD were 7.53±0.244, 8.5±0.29, 8.53±0.5, and 10.52±0.33 μm in neurons in which both the somal and axonal compartments were supplemented with exosomes derived from non-OGD astrocytes, OGD astrocytes, and OGD astrocytes treated with 0.1 and 1 μmol/L Sema3A-I, respectively. Axonal lengths from baseline to 300 minutes were robustly longer in neurons treated with exosomes derived from OGD astrocytes treated with 1 μmol/L Sema3A-I (104.48±5.44 μm) compared with neurons treated with exosomes derived from non-OGD astrocytes, OGD astrocytes, and OGD astrocytes treated with 0.1 μmol/L Sema3A-I (versus 75.04±4.54 versus 85.03±5.08 versus 85.29±5.57; Figure 5B and 5C). Likewise, exosomes from OGD astrocytes treated with 1 μmol/L Sema3A-I substantially increased the axonal elongation rate and total axonal lengths when exosomes were placed in the somal compartment (10.45±0.51 μm per 30 minutes, and 104.52±5.41 μm) or in the axonal compartment (10.56±0.37 μm per 30 minutes, and 105.64±5.33 μm; Figure 5B and 5C).
We further performed microarray analysis using samples from cultured OGD neurons treated with OGD astrocyte-derived exosomes and exosomes derived from OGD astrocytes treated with 1 μmol/L Sema3A-I. Gene expression profiling showed that 14 genes with fold changes >2.0 and P<0.05 were found (Table V in the online-only Data Supplement). Among them, 5 known genes, including defb10, ptgds, slc22a8, cyp11b3, and gjb6, were identified, and the expression of ptgds was highest (Table V in the online-only Data Supplement). Western blotting showed that protein levels of PTGDS were not different between OGD-challenged neurons treated with OGD astrocyte-derived exosomes and exosomes derived from OGD astrocytes treated with 1 μmol/L Sema3A-I. Collectively, the Sema3A-I suppressed activation of astrocytes and Sema3A expression and mediated the functional role of secreted exosomes to further elongate axons together with ptgds expression after ischemia. Western blotting showed that protein levels of pNFH were increased in OGD neurons treated with exosomes derived from OGD astrocytes treated with the Sema3A-I, whereas protein levels of PTGDS were not different ( Figure 6A ).
Expression of pGSK-3β and PTGDS in the Peri-Infarct Area
Double immunostaining revealed that pGSK-3β was expressed in MAP2 + neurons in the peri-infarct area, and the Sema3A-I increased pGSK-3β + and pGSK-3β + -MAP2 + neurons in a dose-dependent manner (0.1 mg/mL, 161.5% and 155.1%; 1 mg/mL, 174.3% and 194.9%; 3 mg/mL, 350.9% and 377.1%, respectively; Figure 6B ). PTGDS was also expressed in MAP2 + neurons, and the Sema3A-I increased PTGDS + and PTGDS + -MAP2 + neurons (0.1 mg/mL, 118.6% and 95.6%; 1 mg/mL, 136.6% and 115.3%; 3 mg/mL, 198.9% and 179.1%, respectively; Figure 6C ). To assess the linkage between pGSK-3β and PTGDS in the effects of Sema3A inhibition of axonal outgrowth after ischemia, we treated MCAO rats with a PTGDS inhibitor together with the Sema3A-I. The expression of PTGDS + neurons and PTGDS + -MAP2 + neurons was significantly decreased in rats treated with 3 mg/mL Sema3A-I and 1 mg/kg PTGDS-I compared with rats treated with 3 mg/mL Sema3A-I only. However, pGSK-3β + neurons and pGSK-3β + -MAP2 + neurons were not significantly decreased after treatment with 1 mg/kg PTGDS-I ( Figure 6B and 6C) . Our data show that pGSK-3β + and PTGDS + neurons were robustly increased, and pGSK-3β and PTGDS were not related to each other in the process of axonal outgrowth during inhibition of Sema3A in the periinfarct area in vivo.
Discussion
The present study demonstrates that in the rodent ischemic brain, inhibition of Sema3A in the subacute phase of stroke substantially increased pNFH + axons and neuronal GSK-3β and PTGDS, suppressed activated astrocytes in the peri-infarct cortex, and enhanced functional recovery during the recovery period. In vitro data show that Rnd1/R-Ras/Akt/GSK-3β signaling and localization of GSK-3β in axons promoted axonal 
Stroke
October 2018
outgrowth of cortical neurons challenged with OGD after treatment with the Sema3A-I. Furthermore, exosomes derived from ischemic astrocytes treated with the Sema3A-I further enhanced axonal outgrowth and ptgds expression. These findings suggest that not only neuronal Rnd1/R-Ras/Akt/GSK-3β signaling but also astrocyte-derived exosomes with PTGDS could be a potential therapeutic target for promoting axonal regrowth and stroke recovery. Sema3A induces growth cone collapse and inhibits axonal regrowth after central nervous system injury, whereas + and S100β + cells. B, Quantitative data of the density of GFAP + cells and S100β + cells. C, Representative Western blots showing protein levels of GFAP, S100β, and Sema3A in non-OGD astrocytes, OGD astrocytes, and OGD astrocytes treated with 1 µmol/L Sema3A-I. β-Actin was used as an internal control. n=3/group. Values are the mean±SD. *P<0.05, ***P<0.001 vs non-OGD astrocytes; #P<0.05, vs OGD astrocytes. Scale bars, 50 µm.
Sema3A is critical during neural development and induces positive dendritic growth. 11, 20, 21 During the degenerative process after axotomy of the optic nerve and spinal cord injuries, Sema3A is involved in scar tissue formation and is expressed in neurons in ischemic brains. 18, 22, 23 Inhibition of Sema3A improves functional recovery after spinal cord injury. 18 The 
October 2018 underlying cellular and molecular mechanisms by which Sema3A regulates axonal outgrowth after ischemia are not fully understood. The present study illuminates novel mechanisms associated with inhibition of Sema3A, especially in the regulation of astrocyte-derived exosomes to enhance axonal regeneration and stroke recovery.
A previous study has shown that axonal regrowth is related to Akt/GSK-3β signaling in the peri-infarct area at 56 days in rat MCAO models. 3 Activation of Akt and subsequent phosphorylation-mediated inhibition of GSK-3β enhances axonal outgrowth. 24 Akt/GSK-3β signaling is thus an important mechanism of axonal regeneration after ischemia. Among the many target proteins involved in signaling downstream of Sema3A through the NRP1/PlexA1 complex, Rnd1 and R-Ras are related to Akt/GSK-3β signaling. Sema3A activity mediates binding of Rnd1 to PlexA1 and suppresses R-Ras, which inhibits Akt/GSK-3β signaling. 11 Our results demonstrate that the Sema3A-I downregulated Rnd1 and upregulated R-Ras, and in turn activated Akt and pGSK-3β, which thereby increased pNFH. More importantly, we observed dynamic expression of pGSK-3β in axons in cortical neurons in vitro. In the peri-infarct area of MCAO rats, the Sema3A-I robustly increased pGSK-3β expression in neurons together with an increase in pNFH + axons. However, GSK-3β regulates CRMP-2 at Thr-514, which in turn induces microtubule disassembly and growth cone collapse in axons; cyclindependent kinase 5 inactivates CRMP-2 at Ser-522. 11, 12, 25 Thus, the dual phosphorylation of CRMP-2 at Ser-522 by cyclin-dependent kinase 5 and at Thr-514 by GSK-3β regulates Sema3A-induced growth cone collapse. 26 In our results, pCRMP-2 at both Thr-514 and Ser-522 was unchanged after Sema3A-I treatment, and therefore GSK-3β but not CRMP-2 was critically implicated in the mechanisms of axonal outgrowth induced by the Sema3A-I after ischemia. The present study demonstrated that neuronal Rnd1/R-Ras/Akt/GSK-3β signaling and axonal GSK-3β expression are implicated in the mechanisms of axonal outgrowth after Sema3A-I treatment in ischemic rat brain for the first time.
Astrocyte activation and scar formation are induced by stroke and can be a barrier to axonal regeneration after stroke. 6, 7 Several signals, including Nogo, are related to astrocyte activation after stroke. 27, 28 Our data showed that the Sema3A-I suppressed accumulation of GFAP + astrocytes in the peri-infarct area of MCAO rats. In cultured astrocytes, the Sema3A-I suppressed GFAP induced by OGD concurrent with inhibition of Sema3A. Previous studies demonstrated that Sema3A in astrocytes contributes to development of neuronal circuit organization in neonatal spinal cord and regenerative processes in amyotrophic lateral sclerosis. 29, 30 Interestingly, the present study demonstrates that the Sema3A-I enhanced the function of astrocyte-derived exosomes for further axonal outgrowth. Glial-derived exosomes secrete synapsin I and promote neurite outgrowth under ischemic conditions. 31 Exosomes derived from mesenchymal stem cells that overexpress microRNAs enhance neurogenesis after stroke. 13, 17 Our microarray analysis demonstrates that ptgds mRNA was highly expressed and identified ptgds as a candidate gene for axonal outgrowth enhanced by exosomes derived from OGD astrocytes treated with the Sema3A-I in cultured cortical neurons after OGD. However, expression of PTGDS protein did not differ between OGD astrocyte-derived exosomes and exosomes derived from OGD astrocytes treated with the Sema3A-I. In the peri-infarct area of MCAO rats, PTGDS immunoreactive neurons were increased by Sema3A-I treatment together with a substantial increase in pNFH axons and suppression of activated astrocytes. PTGDS, acting as not only a PGD2-synthesizing enzyme but also as an extracellular transporter of small lipophilic molecules, is related to several neurological disorders, such multiple sclerosis. 32 More recent evidence shows that PTGDS regulates axonal myelination and remyelination after injury and is neuroprotective. 32, 33 ptgds mRNA is upregulated inside neurons, whereas PTGDS protein is secreted in vitro, indicating that mRNA and protein levels of PTGDS do not correlate. 32, 33 As far as we know, this is the first study to demonstrate that suppression of activated astrocytes and regulation of astrocyte-derived exosomes by treatment with Sema3A promoted further axonal outgrowth together with PTGDS upregulation after stroke. However, miR-30c-2-3p and miR-326-5p were significantly downregulated in exosomes derived from OGD astrocytes treated with the Sema3A-I. Current evidence shows that miR-30c-2-3p and miR-326-5p can be expressed in astrocytes, but the details of the mechanisms of axonal outgrowth, especially in relation to ptgds after ischemia, are unknown.
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Summary
The present study demonstrates that not only regulation of neuronal signaling but also suppression of activated astrocytes and function of astrocyte-derived exosomes play critical roles in axonal outgrowth after stroke. The safety and efficacy of the Sema3A-I after stroke require further study using large sample size. Such future research may facilitate the development of possible treatment agents for ischemic stroke in humans.
